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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
phonophoresis using NSAIDs reduces osteoarthritis knee pain.
Study Design: Systematic review of three double-blind randomized controlled trials published
between the years 2013 and 2018.
Data Sources: Published peer-reviewed articles obtained through PubMed and Cochrane
Collaboration. Articles were selected based on relevance to my clinical question and if they
included patient-oriented outcomes.
Outcomes Measured: Pain severity was self-reported by patients using a visual analog scale
(VAS) on a continuum of 0-100; 0 representing no pain at all and 100 representing the worst
pain imaginable. Participants in all three studies reported pain scores at baseline and after
completing 2 weeks of treatment.
Results: The study conducted by Luksurapan et al. showed a mean change from baseline of
67%, a mean of between group difference of 14.73 +/- 5.78, and a P-value of 0.009.1 The study
conducted by Monisha et al. showed a mean change from baseline of 70% and a P-value < 0.00.2
The study conducted by Oktayoglu et al. showed a mean change from baseline of 23 and a Pvalue of < 0.05.3
Conclusion: All three studies in this EBM review demonstrated reduction of mild to moderate
osteoarthritis knee pain with the use of phonophoresis using NSAIDs. Additional research may
be indicated to further evaluate treatment outcomes with larger and more diverse patient
populations, as well as long-term effects of treatment.
Key Words: Phonophoresis, Osteoarthritis.
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INTRODUCTION
Osteoarthritis (OA) is a chronic and progressive degenerative disease in which joint
spaces are disrupted due to osteophytic lesions, subchondral sclerosis and cartilaginous
erosions.2,3 Osteoarthritis is the most common cause of disability in adults and can lead to
impairment in mobility, pain, and decreased quality of life.3,4 Hip and knee OA cause the greatest
burden in terms of pain, stiffness, and functional disability, which may cause limitations in
activities of daily living and the need for prosthetic joint replacements.2,4
Osteoarthritis is the most common joint disorder in the US and affects over 30 million
adults; up to 13.5% of men and 18.7% of women.4 Etiology of OA may be multifactorial and
some causes may include injuries, overuse of joints, increasing age, poor diet, obesity, genetics,
female gender, congenital or developmental abnormalities, joint misalignment or muscle
weakness.5 The incidence of OA is increasing, likely due to the aging population and the
increased prevalence of obesity.4 OA accounts for approximately 11,127 office visits annually in
the US.7 In 2012, osteoarthritis accounted for the highest cause of work loss, affecting more than
20 million people in the work force and costing the US economy over $100 billion annually.4 In
2013, knee osteoarthritis alone was estimated to contribute to over $27 billion in health care
expenditures annually.4
The goal of treatment for knee OA is focused on pain relief, improving joint function,
and modifying controllable risk factors.6 There are currently no disease modifying drugs
available to treat OA, but there are multiple symptomatic treatment options available for
improvement of pain and function.6 Nonpharmacologic treatment options include physical
therapy, exercise, weight loss, walking aids and braces to alter joint loading.6 Pharmacological
treatment options include topical non-steroidal anti-inflammatory drugs (NSAIDs), topical
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Capsaicin cream, Acetaminophen, oral NSAIDs, oral Cyclooxygenase-2 (COX-2) inhibitors,
intraarticular corticosteroids, and hyaluronic acid injections.6 Other treatment options include
acupuncture, transcutaneous electrical nerve stimulator (TENS), ultrasound, iontophoresis, and
surgery; total joint replacement and arthroscopic debridement.6 Using a combination of
therapeutic approaches is preferred as drug options typically have more potential risk for adverse
effects.6
Phonophoresis using NSAIDs may be used as an alternative treatment option for the
reduction of osteoarthritis knee pain. Phonophoresis uses ultrasound to enhance percutaneous
absorption of drugs.1 Ultrasound is a deep heating agent that can reduce pain by inducing tissue
regeneration, reducing inflammation, and relaxing muscle tissue.1 Phonophoresis can use these
therapeutic factors with the addition of NSAIDs, such as piroxicam or diclofenac
dimethylamonium gel, to enhance reduction of pain and inflammation.1 This therapeutic method
has the advantage of providing local treatment without the renal, cardiac, and gastrointestinal
side effects of oral medications.3 Administration of topical NSAID agents can be used to
maintain stable plasma levels while also maintaining a good safety profile.8 This paper evaluates
three double-blind randomized controlled trials comparing the efficacy of phonophoresis using
NSAIDs in the reduction of osteoarthritis knee pain.
OBJECTIVE
The objective of this selective evidence-based medicine (EBM) review is to determine
whether or not phonophoresis using NSAIDs reduces osteoarthritis knee pain.
METHODS
The articles selected for this systematic review include three double-blind randomized
controlled trials. The population consists of patients with osteoarthritis knee pain. The treatment
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group receiving phonophoresis using NSAID gel was compared to the experimental group
receiving ultrasound with nonpharmacologic gel. Outcomes were measured using a visual analog
scale (VAS) to assess the efficacy of phonophoresis with NSAIDs on the reduction of
osteoarthritis knee pain.
“Phonophoresis” and “osteoarthritis” were the keywords used to find appropriate articles
for this review through PubMed and Cochrane databases. All articles obtained were written in
English and were published in peer reviewed journals between the years 2013 and 2018. Articles
were selected based on their relevance to my clinical question and if they included patientoriented outcomes. Inclusion criteria included randomized control trials published after 2008 and
studies evaluating osteoarthritis and phonophoresis using NSAIDs. Exclusion criteria included
articles published in 2008 or earlier. Statistics reported include p-value and mean change from
baseline.
OUTCOMES MEASURED
Outcomes were measured using a visual analog scale, where pain severity was selfreported by patients across a continuum on a scale of 0-100; 0 representing no pain at all and 100
representing the worst pain imaginable. The VAS was completed at baseline and after two weeks
of treatment to assess efficacy of the intervention compared to the control group. Outcomes were
measured 2 days after the final treatment session to avoid short-term effects of heat application.1
Additionally, the study completed by Oktayoglu et al.3 included further follow up at one, two,
and three months post-treatment to evaluate longer term effects of treatment intervention.
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Table 1: Demographics and characteristics of included studies
Study

Type

#
Pts
46

Age
(yrs)
26-78

Inclusion
Criteria
All patients
fulfilled
American
College of
Rheumatology
criteria for knee
OA, Kellgren
and Lawrence
scores between
I-III, VAS score
> 50

Luksurapan1
(2013)

Double
blind RCT

Monisha2
(2018)

Double
blind RCT

50

40-70

Age 40-70,
Baseline VAS
score of 10

Oktayoglu3
(2014)

Prospective
RCT

40

54.55
+ 8.6

All patients
fulfilled
American
College of
Rheumatology
criteria for knee
OA, Kellgren
and Lawrence
scores between
II-IV, VAS
score > 50 with
either walking,
knee flexion, or
resting

Exclusion
Criteria
Knee pain not
due to OA,
chronic systemic
inflammatory
diseases, allergy
to piroxicam,
recent knee
injury or surgery,
using NSAIDs,
corticosteroids,
or tramadol
hydrochloride
Knee pain not
due to OA,
chronic systemic
inflammatory
diseases, allergy
to piroxicam,
history of knee
injury or surgery,
VAS score < 10,
using NSAIDs or
corticosteroids
Secondary OA,
intraarticular or
intramuscular
corticosteroids,
intraarticular
hyaluronic acid
in the past 3
months, allergy
to NSAIDs,
physical therapy
in the past 6
months, systemic
or malignant
diseases,
abnormal lab
results,
dermatological
problems, using
NSAIDs or other
analgesic drugs

W/D

Interventions

0

Continuous
Phonophoresis
with piroxicam
gel for the
duration of 10
minutes, 5 times a
week for 2 weeks.
Ultrasonic wave
frequency of 1
MHz and power
of 1 W/cm2

0

Continuous
Phonophoresis
with piroxicam
gel for the
duration of 10
minutes, 5 times a
week for 2 weeks.
Ultrasonic wave
frequency of 1
MHz and power
of 1 W/cm2
Continuous
Phonophoresis
with diclofenac
diethylamonium
gel for the
duration of 10
minutes, 5 times a
week for 2 weeks.
Ultrasonic wave
frequency of 1
MHz and power
of 1.5 W/cm2

0
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RESULTS
All three studies compared the efficacy of continuous phonophoresis with an NSAID
based gel, either piroxicam or diclofenac diethylamonium, to nonpharmacologic ultrasound gel.
Phonophoresis was generally well tolerated, without reports of any serious side effects. A total of
10 sessions were completed, five times a week for two consecutive weeks for the duration of 10
minutes each session. Studies conducted by Luksurapan et al. and Monisha et al. used ultrasonic
wave frequency of 1 MHz and power of 1 W/cm2, whereas the study conducted by Oktayoglu et
al. used a wave frequency of 1 MHz and power of 1.5 W/cm2.1,2,3 All three studies used the
visual analog scale to evaluate a mean change from baseline and to obtain a P-value to determine
statistical significance of phonophoresis compared to ultrasound in OA pain reduction.
The first study conducted by Luksurapan et al. was a double blind randomized controlled
trial consisting of 45 females and 1 male between the ages of 26 and 78, with a median age of 59
years.1 Each group being studied consisted of 23 individuals that fulfilled the American College
of Rheumatology criteria for knee OA, Kellgren and Lawrence scores between I-III, and a VAS
score > 50.1 Exclusion criteria is listed in Table 1. There were no significant differences between
each group in terms of duration of knee pain, hours of weight-bearing activity, or KellgrenLawrence scores.1 All participants in both study groups completed their allocated treatment
without any dropouts.1 Everyone in the phonophoresis group completed all 10 treatment
sessions, whereas 2 individuals in the ultrasound group completed 7 and 9 of the 10 treatment
sessions.1 ANCOVA was used to adjust for the imbalance of treatment sessions attended.1
Patients in the phonophoresis group received 20 mg of 0.5% piroxicam gel, whereas standard
coupling gel was used in the control group.1 As seen in Table 2, both groups showed significant
change in their VAS scores, indicating decreased OA knee pain.1 The phonophoresis group
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presented with a significant reduction of pain and a mean change from baseline of 67%
compared to the control group receiving ultrasound, with a mean change from baseline of 39%.1
The mean of between group difference was 14.73 +/- 5.78 with a p-value of 0.009.1 While this
data shows strong statistical significance, there is a wide 95% confidence interval (5.99-30.27),
which may indicate a less precise estimate of the treatment effect due to a small sample size.1
Table 2: Mean Change from Baseline and Statistical Significance, Luksurapan1
Baseline

Post-Treatment

Phonophoresis

70.57 +/- 12.03

23.57 +/- 19.27

Mean Change from
Baseline
67%

Ultrasound

72.48 +/- 12.33

43.91 +/- 25.19

39%

P-value
0.009

The second study conducted by Monisha et al. was a double blind randomized controlled
trial consisting of a total of 50 women between the ages of 40 and 70 years.2 Participants were
randomly allocated to 3 different treatment groups, two of which are the focus of this review.2
One group received phonophoresis with piroxicam gel and standard coupling gel in a 4:10 ratio,
whereas the control group received ultrasound with an aquasonic gel.2 There was no mention of
the number of individuals allocated to each treatment group or if there were any dropouts over
the duration of this study. Inclusion criteria included a baseline VAS score of at least 10 and
exclusion criteria is listed in Table 1. VAS scores of both groups, demonstrated in Table 3, show
an improvement of mild to moderate OA knee pain when compared to baseline scores. The
phonophoresis group showed a significant improvement of knee pain with a mean change from
baseline of 70%, compared to the ultrasound group which showed a mean change from baseline
of 50%.2 The p-value reported in this study was < 0.00, which indicates a strong statistical
significance.2
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Table 3: Mean Change from Baseline and Statistical Significance, Monisha2
Baseline

Post-Treatment

Phonophoresis

75

25

Mean Change from
Baseline
70%

Ultrasound

73

50

50%

P-value
< 0.00

The third study conducted by Oktayoglu et al. was a prospective randomized controlled
trial consisting of 40 participants, 10 men and 30 women.3 The phonophoresis group consisted of
13 women and 7 men with an average age of 54.55 +/- 8.65 years, whereas the ultrasound group
consisted of 17 women and 3 men with an average age of 55.05 +/- 10.08 years.3 A non-treating
author randomly allocated participants into each group, however there was no mention on
whether or not patients, clinicians, and study workers were kept blind to treatment.3 All
participants fulfilled the American College of Rheumatology criteria for knee osteoarthritis, had
Kellgren-Lawrence scores between II-IV and VAS scores above 50.3 Exclusion criteria is listed
in Table 1. There was not a significant difference in demographic data or pre-trial clinical
parameters between the two study groups.3 The phonophoresis group received 1.16% diclofenac
diethylamonium gel and the ultrasound group received a nonpharmacologic acoustic gel.3 VAS
scores of walking, resting and flexion movement were obtained at baseline, post-treatment at 2
weeks, and at one, two, and three months following treatment.3 There was no mention of
dropouts over the duration of this study. For the purpose of this review, data in Table 4 presents
walking VAS scores. As seen in Table 4, improvements were examined in VAS scores in both
the phonophoresis and ultrasound groups during all follow up times.3 Both groups had
comparable VAS scores from baseline to post-treatment at 2 weeks.3 At one month follow up,
the phonophoresis group was shown to be superior to the ultrasound group when comparing
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walking VAS scores, with a mean change from baseline of 23 compared to 10, respectively.3
Statistical significance is demonstrated with a p-value of less than 0.05.3
Table 4: Mean Change from Baseline and Statistical Significance, Oktayoglu3
Baseline
Phonophoresis

64.5 +/- 14.68

Ultrasound

61 +/- 13.72

PostTreatment
52 +/- 12.81
P-value: 0.002
50 +/- 11.23
P-value: 0.001

1 month follow
up
41.5 +/- 19.8
P-value: 0.001
51 +/- 11.19
P-value: 0.003

2 month follow
up
47 +/- 22.73
P-value: 0.002
52.5 +/- 7.86
P-value: 0.007

3 month follow
up
47.74 +/- 19.89
P-value: 0.003
53.5 +/- 9.33
P-value: 0.024

DISCUSSION
The objective of this systematic EBM review is to determine whether or not
phonophoresis using NSAIDs reduces osteoarthritis knee pain. Each study used a visual analog
scale to evaluate pain at baseline and after two weeks of treatment with either phonophoresis or
nonpharmacologic ultrasound. Each study measured VAS outcomes two days after completion of
treatment to avoid any short-term effects of heat application.1,2,3 The study conducted by
Oktayoglu et al. additionally examined one, two, and three months follow up of treatment. This
study showed promising results at one month follow up, but additional studies are needed to
further evaluate long term effects of phonophoresis and to determine appropriate frequency of
treatment. While this treatment option may be relatively inexpensive and well tolerated, there
may be issues with poor compliance if patients are required to be present for treatment 5 days a
week for two consecutive weeks. Phonophoresis should be administered for at least 10 minutes
each session, as shorter application times have been proven to be ineffective.8 This may be a
limitation to providers who do not have sufficient time or personnel to help administer this
treatment effectively.
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Phonophoresis is noninvasive and simple to administer, which makes this treatment
modality a great option for both patients and providers. While OA affects a wide range of
patients, phonophoresis could be used in a variety of primary care settings, and not limited to
physical therapy clinics. The sample size in all three studies ranged from 40-50 participants,
which is relatively small. Evaluating larger experimental groups may be beneficial in assessing
outcomes, as outliers in the study will not affect the results as much as they do in smaller sample
sizes. The study conducted by Monisha et al. only examined female patients and the studies
conducted by Luksurapan et al. and Oktayoglu et al. were female predominant. Studies have
shown that male and female responses to treatment of pain may differ, indicating that the studies
being reviewed in this paper may not have the ability to generalize these results to the general
population.1
Phonophoresis may be used to enhance transcutaneous delivery of NSAIDs to block
nociceptive and neuropathic pain.8 One study determined that diclofenac had the smallest flow
and permeability, when compared to ibuprofen 5% and piroxicam, making it more efficacious in
pain reduction.8 Additional studies may be needed to determine which NSAID should be used to
achieve maximum absorption and effectiveness. It may also be beneficial to have additional
studies to compare outcomes using the same type of NSAID gel for phonophoresis in each
experimental group. Luksurapan et al. and Monisha et al. used different ultrasound parameters in
terms of power when compared to Oktayoglu et al., which could also facilitate different results in
terms of percutaneous drug diffusion.1 Standardization of ultrasound wave frequency and power
would help make these studies more comparable.
According to the Food and Drug Administration (FDA), ultrasonic therapy devices must
comply with medical device regulations and radiation safety performance standards, although
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phonophoresis and ultrasonic diathermy devices have not been formally evaluated and
approved.11 Phonophoresis is still considered experimental and investigational by insurance
companies, which may limit coverage of this treatment and become a financial barrier to some
patients.
Diclofenac gel is an approved treatment option for acute pain, osteoarthritis, and actinic
keratosis.9 Skin irritation, including pruritis, contact dermatitis, application site pain, and
desquamation, is a frequently reported side effect of this medication.9 Topical diclofenac gel is
contraindicated in those with hypersensitivity to diclofenac or history of asthma, urticaria, or
other allergic reactions to NSAIDs, open skin wounds, infections, or damaged skin.9 Other
possible adverse reactions of topical diclofenac gel may include elevated liver function enzymes,
gastrointestinal upset, and central nervous system effects such as headache, paresthesia, and
hyperesthesia.9 Black box warnings for topical diclofenac include cardiovascular thrombotic
events, gastrointestinal bleeding, ulceration, and perforation, although these risks are
significantly lower than use of oral NSAIDs.6,9 NSAIDs should be avoided starting at 30 weeks
of pregnancy due to risk of premature closure of fetal ductus arteriosus, although topical
application of diclofenac crosses the placenta to a lesser extent than systemic use.9 It is unknown
on whether or not use of topical diclofenac will be detected in breast milk, whereas it may be
present with systemic use.9 Less information is given specifically for topical piroxicam, although
breastfeeding is not recommended.10
CONCLUSION
All three studies demonstrated conclusive evidence in short-term reduction of mild to
moderate osteoarthritis knee pain with the use of phonophoresis using NSAIDs. Additional
studies should to be completed to address limitations as mentioned and obtain more data
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regarding this topic of study. Future experimental trials may benefit from evaluating treatment
response from larger study groups and more diverse patient populations in terms of gender. From
a clinical standpoint, it may also be beneficial to evaluate longer term effects of treatment. When
non-pharmacological treatment options have failed or are no longer an option, oral NSAIDs,
intraarticular steroids, and surgery are still some of the most commonly used treatments.
Enhancing topical NSAID absorption via phonophoresis may be a great, safe alternative
treatment option.
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